NASDAQ:LIXT Lixte Biotechnology (LIXT) Stock Price, News & Analysis $1.98 +0.07 (+3.66%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends About Lixte Biotechnology Stock (NASDAQ:LIXT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lixte Biotechnology alerts:Sign Up Key Stats Today's Range$1.85▼$2.1450-Day Range$1.31▼$2.3852-Week Range$1.31▼$4.40Volume7,186 shsAverage Volume316,736 shsMarket Capitalization$4.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewLIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Read More… Receive LIXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address LIXT Stock News HeadlinesMercantile Bank (NASDAQ:MBWM) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comStryve Foods (NASDAQ:SNAX) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.December 22, 2024 | Porter & Company (Ad)LIXTE Receives U.S. Patent Issue Notification for Immune OncologySeptember 4, 2024 | globenewswire.comFirst Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma CompanyAugust 26, 2024 | finance.yahoo.comFirst Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma CompanyAugust 26, 2024 | globenewswire.comLIXTE Biotechnology Provides Update On Recent Activities and DevelopmentsAugust 19, 2024 | globenewswire.comLIXT Stock Earnings: Lixte Biotech Hldgs Reported Results for Q2 2024August 16, 2024 | investorplace.comSee More Headlines LIXT Stock Analysis - Frequently Asked Questions How have LIXT shares performed this year? Lixte Biotechnology's stock was trading at $2.35 at the beginning of 2024. Since then, LIXT shares have decreased by 15.7% and is now trading at $1.98. View the best growth stocks for 2024 here. How were Lixte Biotechnology's earnings last quarter? Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) announced its quarterly earnings results on Friday, November, 4th. The company reported ($0.10) earnings per share (EPS) for the quarter. When did Lixte Biotechnology's stock split? Shares of Lixte Biotechnology reverse split before market open on Monday, June 5th 2023. The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Lixte Biotechnology IPO? Lixte Biotechnology (LIXT) raised $7 million in an initial public offering on Wednesday, November 25th 2020. The company issued 1,500,000 shares at a price of $4.75 per share. WestPark Capital and WallachBeth Capital served as the underwriters for the IPO. How do I buy shares of Lixte Biotechnology? Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lixte Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lixte Biotechnology investors own include Predictive Oncology (POAI), Sangamo Therapeutics (SGMO), Ford Motor (F), Insulet (PODD), Energy Select Sector SPDR Fund (XLE), Zomedica (ZOM) and Abbott Laboratories (ABT). Company Calendar Last Earnings11/04/2016Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LIXT CUSIPN/A CIK1335105 Webwww.lixte.com Phone(631) 830-7092Fax631-982-5050Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-5,562.77% Return on Assets-130.48% Debt Debt-to-Equity RatioN/A Current Ratio5.13 Quick Ratio5.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book9.00Miscellaneous Outstanding Shares2,249,000Free Float1,916,000Market Cap$4.45 million OptionableNot Optionable Beta-0.11 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:LIXT) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts no...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.